More information, please [Study As­sess­ment]

posted by AngusMcLean – USA, 2016-05-13 16:40  – Posting: # 16301
Views: 16,528

Hello: It is a very well known drug and many MR formulations are on the market. (You have experience with this drug). All except one formulation show dose proportionality from lowest to highest strength. The one which does not is almost dose proportional. We used that in our clinical protocol to justify our study design of using just two doses. We do have intermediate doses between the low and the high.


There are only two does levels to plot. The relationship is as follows:

LnPK=B0+B1*Ln(dose) where LnPK pertains to Cmax or AUC.

So we have a regression line going through the points: we evaluate the slope (B1), intercept and the confidence intervals about the slope to evaluate dose proportionality. Brian Smith in Pharm Research year 2000 has extended the approach from the original UK working party. It seems that you can calculate intrasubject and intersubject variance e.g. for AUC and partial AUC from this approach. I do not follow how to do it. I use the usual intrasubject and intersubject values from Phoenix WinNonlin 6.4 and I am happy with that.

Angus

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,537 posts in 4,144 threads, 1,338 registered users;
online 16 (0 registered, 16 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 17:25 CEST

When puzzled, it never hurts to read the primary documents –
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5